English
SpanishTrusted Resources: Evidence & Education
Scientific literature and patient education texts
Thyroid Surgery for Graves’ Disease and Graves’ Ophthalmopathy
source: The Cochrane Database of Systematic Reviews
year: 2015
authors: Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K
summary/abstract:Background:
Graves’ disease is an autoimmune disease caused by the production of auto-antibodies against the thyroid-stimulating hormone receptor, which stimulates follicular cell production of thyroid hormone. It is the commonest cause of hyperthyroidism and may cause considerable morbidity with increased risk of cardiovascular and respiratory adverse events. Five per cent of people with Graves’ disease develop moderate to severe Graves’ ophthalmopathy. Thyroid surgery for Graves’ disease commonly falls into one of three categories: 1) total thyroidectomy, which aims to achieve complete macroscopic removal of thyroid tissue; 2) bilateral subtotal thyroidectomy, in which bilateral thyroid remnants are left; and 3) unilateral total and contralateral subtotal thyroidectomy, or the Dunhill procedure.
Recent American Thyroid Association guidelines on treatment of Graves’ hyperthyroidism emphasised the role of surgery as one of the first-line treatments. Total thyroidectomy removes target tissue for the thyroid-stimulating hormone receptor antibody. It controls hyperthyroidism at the cost of lifelong thyroxine replacement. Subtotal thyroidectomy leaves a thyroid remnant and may be less likely to lead to complications, however a higher rate of recurrent hyperthyroidism is expected and revision surgery would be challenging. The choice of the thyroidectomy technique is currently largely a matter of surgeon preference, and a systematic review of the evidence base is required to determine which option offers the best outcomes for patients.
organization: Whipps Cross University Hospital, UKDOI: 10.1002/14651858.CD010576.pub2
read more full text
myBinderRelated Content
-
Predictive Score for the Development or Progression of Graves’ Orbitopathy in Patients With Newly Diagnosed Gr...Objective: To construct a predictive sc...
-
Risk Factors for Graves’ Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study.Context: Previous association studies s...
-
Graves’ Eye Disease FAQWhat is the Thyroid Gland? The thyroid ...
-
Cost-Utility Analysis Comparing Radioactive Iodine, Anti-Thyroid Drugs and Total Thyroidectomy for Primary Treatment...Objective: Little data is in existence ...
-
Dealing With Thyroid Eye Disease: Patient and Physician PerspectivesJoin us for a webinar hosted by the Grav...
-
Catherine J. Hwang, MDDr. Catherine J. Hwang was born in New Y...
-
Recent Developments in Graves’ OphthalmopathyRecent Developments in Graves' ophthalmo...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
